Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CDA | P32320 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21980556 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| SCHEMBL30591063 | 0.99 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| SCHEMBL26109184 | 0.92 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23869401 | 0.90 | UMPS (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL31685475 | 0.88 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| SCHEMBL23666552 | 0.88 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| SCHEMBL8402713 | 0.86 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| SCHEMBL8402712 | 0.86 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| SCHEMBL18574266 | 0.86 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| SCHEMBL14929312 | 0.86 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2558 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277223-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2025-09-04 | — | — | US | claimed |
| US-12398379-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4598935-A2 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| CN-110719787-A | RNA for treating autoimmune diseases | 生物技术RNA制药有限公司 | 2020-01-21 | — | — | CN | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| US-20190175690-A1 | COMPOSITIONS AND METHODS FOR CARDIAC REPAIR | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-06-13 | — | — | US | claimed |
| EP-3460064-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | The General Hospital Corporation d/b/a Massachusetts General Hospital (US) | 2019-03-27 | — | — | EP | claimed |
| US-10086043-B2 | Efficient protein expression in vivo using modified RNA (MOD-RNA) | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-02 | — | — | US | claimed |
| EP-2694660-B1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | MASSACHUSETTS GEN HOSPITAL (US) | 2018-08-08 | — | — | EP | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| US-20140073687-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | IMMUNE DISEASE INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |